Avelumab plus axitinib combination available via EAMS

It has just been announced that the avelumab plus axitinib combination has received positive scientific opinion for the Early Access to Medicines Scheme (EAMS) for the first-line treatment of advanced renal cell carcinoma (RCC). EAMS aims to give patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing […]

read more

Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer

A recent study, published in Clinical Genitourinary Cancer reports a meta-analysis comparing the tolerability and efficacy of a 2 weeks on treatment/1 week off treatment sunitinib dosing schedule with the traditional 4/2 schedule in patients with metastatic renal cell carcinoma (mRCC). Data from 1173 patients were included in the meta-analysis. The study showed that progression-free […]

read more

Nivolumab and kidney cancer brain metastases

Results from a recent trial suggest that nivolumab has limited efficacy against previously untreated brain metastases in patients with metastatic renal cell carcinoma (mRCC). Around 10% of patients with metastatic RCC develop metastases in the brain. Since the results of this trial are negative and do not impact clinical practice, the study brings into question […]

read more

ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders

This study was presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago last month. The trial looked at 103 patients with a variety of different autoimmune disorders, such as psoriasis (22%), thyroiditis (20%), rheumatoid arthritis (13%), polymyalgia rheumatica (8%), inflammatory bowel disease (6%), multiple sclerosis (3%) and lupus (3%) who […]

read more

Current perspectives on non-clear cell kidney cancer

The majority of kidney cancer (around 80%) is characterised as clear-cell renal cell carcinoma (RCC), while the remaining 20% is non-clear cell RCC. Most of these are papillary RCC, but non-clear cell RCC also includes collecting duct, translocation, chromophobe and a variety of other rare tumour types. Because non-clear cell RCC is relatively rare, data […]

read more

NICE exploring ways to use real world data

The National Institute of Health and Care Excellence (NICE) is planning to extend its use of real world data to help inform its independent committees who produce its guidance. NICE already makes use of a wide range of published scientific evidence for its guidance for the NHS on health technologies for a range of medical […]

read more

Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer

Telaglenastat is an oral glutaminase inhibitor and this is the first time it has been administered to humans. Glutaminase is a key enzyme that controls the glutamine pathway that is prominent in renal cell carcinoma (RCC) and important for the tumour to thrive in the body. In pre-clinical models, telaglenastat was found to synergise with […]

read more

Elderly kidney cancer patients benefit from targeted therapies

Elderly patients with metastatic renal cell carcinoma (RCC) are often underrepresented in clinical trials to treat the kidney cancer. However, according to a recent study published in JAMA Network Open Thirteen years of data were analysed from Medicare patients in the USA. Patients who received targeted therapies had more complex medical needs than those who […]

read more

NHS to fast-track cancer drugs that target genetic mutations

The NHS is preparing to fast-track the introduction of ‘game changing’ new cancer drugs that target tumours according to their genetic make-up. These revolutionary new treatments, called ‘tumour agnostic’ drugs, can be used against a wide range of cancers and could offer hope to patients with rare cancers that may previously have been untreatable. Tumour […]

read more

Cytoreductive surgery with immunotherapy for kidney cancer patients

In this video clip, Professor Eric Jonasch, Medical Oncologist, Division of Cancer Medicine at MD Anderson Cancer Center, University of Texas, Houston, speaks about the role of cytoreductive surgery along with immunotherapy for patients who have metastatic renal cell carcinoma (RCC). Watch the video on Practice Update here

read more
Showing 1 to 10 of 357 results
  TOP